It is the data of hospitalizations, the one to observe with greater attention, due to the severity of the emergency. On this front, the situation in San Marino is encouraging, with one Covid-free intensive care, and hospitalizations which pass from two to one. The last year, on the same day, they were altogether 13, people positive for the virus, at the Cailungo hospital; 7 of which in intensive. From this comparison the confirmation ofeffectiveness from the vaccinations, while the campaign for the third dose is in full swing. However, the growth of active cases: 195 – with an average age of 38 -; and this due to the 41 new positivity detected yesterday, compared to 26 healings. 395 swabs were carried out, with a positivity rate that slightly exceeds the psychological threshold of 10%.

Strong circulation of the infection too beyond the border; In the Rimini 100 new cases, and unfortunately 2 deaths. 9 those registered in region; where in the last 24 hours they have been detected 850 positivity. A little more than 10,000 in Italy; 83 the victims, but the count includes 14 deaths, reported by Sicily, which is said in recent days. In the meantime, the possible introduction – on the strong push of the Regions – of the so-called “Super Green Pass“, With strong social activities for those who do not get vaccinated. Some white governors such a measure also in the area It will be decided tomorrow, probably, in Council of Ministries. Also on the table are measures such as the return of the mask outdoors and the obligation to third dose for health care workers. As for the tampons should remain valid for access to workplaces and essential services, but a reduction of the duration. Already decided, however, by the Ministry of Health, theadvance of the “booster” after 5 months from completion of primary school. 4 months in Austria. In these hours, meanwhile, the alarm of theWHO; that speaks of beyond 2 million and 200,000 dead from Covid, in Europe – if action is not taken immediately -, by spring. Finally, news on the pill anticovid of the Merck; L’EMA has begun to underestimate an application for marketing authorization for the medicinal product, the opinion is expected in the weeks.